The Functional Neuroanatomy of Brain Cannabinoid Receptors

The effects of the primary psychoactive constituent of marijuana, delta 9-tetrahydrocannabinol, are mediated by cannabinoid receptors, CB1 and CB2. The CB1 receptors display a unique central nervous system (CNS) distribution and are present in mammalian brain at higher levels than most other known G-protein-coupled receptors. The highest levels occur in several areas involved in motor control and hippocampus. Cannabinoid effects on CNS activities, including movement, memory, nociception, endocrine regulation, thermoregulation, sensory perception, cognitive functions, and mood, correlate with the regional distribution of cannabinoid receptors and their activation of specific G-protein-mediated signal transduction systems in various brain regions.

[1]  H. Yamamura,et al.  SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. , 1997, European journal of pharmacology.

[2]  C. Breivogel,et al.  Regional differences in cannabinoid receptor/G-protein coupling in rat brain. , 1997, The Journal of pharmacology and experimental therapeutics.

[3]  D. Piomelli,et al.  A second endogenous cannabinoid that modulates long-term potentiation , 1997, Nature.

[4]  M. Glass,et al.  Concurrent Stimulation of Cannabinoid Cb1 and Dopamine D2 Receptors Augments Camp Accumulation in Striatal Neurons: Evidence for a G S Linkage to the Cb1 Receptor , 1997 .

[5]  G. Di Chiara,et al.  Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. , 1997, Science.

[6]  G. Koob,et al.  Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. , 1997, Science.

[7]  A. Makriyannis,et al.  Time course of the effects of different cannabimimetics on prolactin and gonadotrophin secretion: evidence for the presence of CB1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics. , 1997, Biochemical pharmacology.

[8]  L. Murphy,et al.  Role of the hypothalamic-pituitary-adrenal axis in the suppression of luteinizing hormone release by delta-9-tetrahydrocannabinol. , 1997, Neuroendocrinology.

[9]  R. Roth,et al.  Δ9-Tetrahydrocannabinol Increases Prefrontal Cortical Catecholaminergic Utilization and Impairs Spatial Working Memory in the Rat: Blockade of Dopaminergic Effects with HA966 , 1997, Neuropsychopharmacology.

[10]  G. Gessa,et al.  Inhibition of hippocampal acetylcholine release by cannabinoids: reversal by SR 141716A. , 1997, European journal of pharmacology.

[11]  E. French Δ 9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors , 1997, Neuroscience Letters.

[12]  R. Quock,et al.  delta 9-Tetrahydrocannabinol is a partial agonist of cannabinoid receptors in mouse brain. , 1997, European journal of pharmacology.

[13]  S. Gatley,et al.  Examination of the effect of the cannabinoid receptor agonist, CP 55,940, on electrically evoked transmitter release from rat brain slices. , 1997, European journal of pharmacology.

[14]  J. Brotchie,et al.  Paradoxical action of the cannabinoid WIN 55,212‐2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices , 1997, British journal of pharmacology.

[15]  J. Walker,et al.  Role of the subthalamic nucleus in cannabinoid actions in the substantia nigra of the rat. , 1997, Journal of neurophysiology.

[16]  R. Faull,et al.  Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain , 1997, Neuroscience.

[17]  R. Pertwee Pharmacology of cannabinoid CB1 and CB2 receptors. , 1997, Pharmacology & therapeutics.

[18]  E. Gardner,et al.  The effect of intravenous administration of delta-9-tetrahydrocannabinol on the activity of A10 dopamine neurons recorded in vivo in anesthetized rats. , 1997, Neuropsychobiology.

[19]  D. Selley,et al.  mu-Opioid receptor-stimulated guanosine-5'-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy. , 1997, Molecular pharmacology.

[20]  R. Hampson,et al.  Effects of Chronic Treatment with Δ9-Tetrahydrocannabinol on Cannabinoid-Stimulated [35S]GTPγS Autoradiography in Rat Brain , 1996, The Journal of Neuroscience.

[21]  A. Hohmann,et al.  Suppression of Noxious Stimulus-Evoked Activity in the Ventral Posterolateral Nucleus of the Thalamus by a Cannabinoid Agonist: Correlation between Electrophysiological and Antinociceptive Effects , 1996, The Journal of Neuroscience.

[22]  J. Orsini,et al.  Neuronal responses to Δ9-tetrahydrocannabinol in the solitary tract nucleus , 1996 .

[23]  H. Rosenberg,et al.  Local pressure application of cannabinoid agonists increases spontaneous activity of rat substantia nigra pars reticulata neurons without affecting response to iontophoretically-applied GABA , 1996, Brain Research.

[24]  S. Childers,et al.  Cannabinoid receptor stimulation of guanosine-5'-O-(3-[35S]thio)triphosphate binding in rat brain membranes. , 1996, Life sciences.

[25]  J. Brotchie,et al.  Activation of the cannabinoid receptor by Δ9-tetrahydrocannabinol reduces γ-aminobutyric acid uptake in the globus pallidus , 1996 .

[26]  M. Shen,et al.  Cannabinoid Receptor Agonists Inhibit Glutamatergic Synaptic Transmission in Rat Hippocampal Cultures , 1996, The Journal of Neuroscience.

[27]  D. Selley,et al.  Differences in G-protein activation by μ-and δ-opioid, and cannabinoid, receptors in rat striatum , 1996 .

[28]  C. Ashby,et al.  Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A. , 1996, The Journal of pharmacology and experimental therapeutics.

[29]  J. Walker,et al.  Electrophysiological effects of a cannabinoid on neural activity in the globus pallidus. , 1996, European journal of pharmacology.

[30]  A. Buriani,et al.  The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J. Brotchie,et al.  Modulation of GABAergic transmission in the globus pallidus by the synthetic cannabinoid WIN 55,212‐2 , 1996, Synapse.

[32]  A. Lichtman,et al.  Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. , 1996, The Journal of pharmacology and experimental therapeutics.

[33]  R. Knapp,et al.  Antisense oligodeoxynucleotide treatment to the brain cannabinoid receptor inhibits antinociception , 1996, Neuroreport.

[34]  K. Mackie,et al.  Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[35]  J. Lowe,et al.  Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A. , 1995, European journal of pharmacology.

[36]  R. Hampson,et al.  Cannabinoids selectively decrease paired-pulse facilitation of perforant path synaptic potentials in the dentate gyrus in vitro , 1995, Brain Research.

[37]  D. Selley,et al.  In vitro autoradiography of receptor-activated G proteins in rat brain by agonist-stimulated guanylyl 5'-[gamma-[35S]thio]-triphosphate binding. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[38]  S. L. Patrick,et al.  Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. , 1995, European journal of pharmacology.

[39]  R. Pertwee,et al.  Prevention by the cannabinoid antagonist, SR141716A, of cannabinoid‐mediated blockade of long‐term potentiation in the rat hippocampal slice , 1995, British journal of pharmacology.

[40]  J. Walker,et al.  Effects of a cannabinoid on spontaneous and evoked neuronal activity in the substantia nigra pars reticulata. , 1995, European journal of pharmacology.

[41]  A. Hohmann,et al.  Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55,212-2. , 1995, Life sciences.

[42]  B. Martin,et al.  Effects of anandamide (endogen cannabinoid) on anterior pituitary hormone secretion in adult ovariectomized rats. , 1995, Life sciences.

[43]  A. Lichtman,et al.  Evaluation of cAMP involvement in cannabinoid-induced antinociception. , 1995, Life sciences.

[44]  S. L. Patrick,et al.  An examination of the central sites of action of cannabinoid-induced antinociception in the rat. , 1995, Life sciences.

[45]  R. Hampson,et al.  Cannabinoids modulate voltage sensitive potassium A-current in hippocampal neurons via a cAMP-dependent process. , 1995, The Journal of pharmacology and experimental therapeutics.

[46]  M. Kaghad,et al.  An Amino-terminal Variant of the Central Cannabinoid Receptor Resulting from Alternative Splicing (*) , 1995, The Journal of Biological Chemistry.

[47]  R. Mechoulam,et al.  Characterization of the hypothermic effect of the synthetic cannabinoid HU-210 in the rat. Relation to the adrenergic system and endogenous pyrogens , 1995, Neuropharmacology.

[48]  P. Fan Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. , 1995, Journal of neurophysiology.

[49]  S. Welch,et al.  Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine. , 1995, The Journal of pharmacology and experimental therapeutics.

[50]  A. Howlett,et al.  Pharmacology of cannabinoid receptors. , 1995, Annual review of pharmacology and toxicology.

[51]  L. Shaw,et al.  Cannabinoids and appetite stimulation , 1994, Pharmacology Biochemistry and Behavior.

[52]  P. Soubrié,et al.  SR141716A, a potent and selective antagonist of the brain cannabinoid receptor , 1994, FEBS letters.

[53]  R. Pertwee,et al.  The action of synthetic cannabinoids on the induction of long-term potentiation in the rat hippocampal slice. , 1994, European journal of pharmacology.

[54]  S. Childers,et al.  Effects of anandamide on cannabinoid receptors in rat brain membranes. , 1994, Biochemical pharmacology.

[55]  S. L. Patrick,et al.  Antinociceptive actions of cannabinoids following intraventricular administration in rats , 1993, Brain Research.

[56]  E. Gardner,et al.  Ventral tegmental microinjection of Δ9-tetrahydrocannabinol enhances ventral tegmental somatodendritic dopamine levels but not forebrain dopamine levels: evidence for local neural action by marijuana's psychoactive ingredient , 1993, Brain Research.

[57]  S. Munro,et al.  Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.

[58]  K. Mackie,et al.  Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. , 1993, Molecular pharmacology.

[59]  S. Welch Blockade of cannabinoid-induced antinociception by norbinaltorphimine, but not N,N-diallyl-tyrosine-Aib-phenylalanine-leucine, ICI 174,864 or naloxone in mice. , 1993, The Journal of pharmacology and experimental therapeutics.

[60]  K. Rice,et al.  Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. , 1993, The Journal of pharmacology and experimental therapeutics.

[61]  S. Childers,et al.  Identification of cannabinoid receptors in cultures of rat cerebellar granule cells , 1993, Brain Research.

[62]  T. Bliss,et al.  A synaptic model of memory: long-term potentiation in the hippocampus , 1993, Nature.

[63]  S A Deadwyler,et al.  Effects of delta-9-tetrahydrocannabinol on delayed match to sample performance in rats: alterations in short-term memory associated with changes in task specific firing of hippocampal cells. , 1993, The Journal of pharmacology and experimental therapeutics.

[64]  D. Gibson,et al.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.

[65]  N. Kaminski,et al.  Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. , 1992, Molecular pharmacology.

[66]  J. Vanderhaeghen,et al.  Distribution of neuronal cannabinoid receptor in the adult rat brain: A comparative receptor binding radioautography and in situ hybridization histochemistry , 1992, Neuroscience.

[67]  K. Mackie,et al.  Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[68]  B. Martin,et al.  Spinal mechanisms ofΔ9-tetrahydrocannabinol-induced analgesia , 1992, Brain Research.

[69]  D. Haycock,et al.  Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles , 1992, Brain Research.

[70]  S. C. Newton,et al.  Evidence for a direct anterior pituitary site of delta-9-tetrahydrocannabinol action , 1991, Pharmacology Biochemistry and Behavior.

[71]  A. Lichtman,et al.  Spinal and supraspinal components of cannabinoid-induced antinociception. , 1991, The Journal of pharmacology and experimental therapeutics.

[72]  M. Herkenham,et al.  Neuronal localization of cannabinoid receptors in the basal ganglia of the rat , 1991, Brain Research.

[73]  S. Childers,et al.  Aminoalkylindoles: actions on specific G-protein-linked receptors. , 1991, The Journal of pharmacology and experimental therapeutics.

[74]  R. Pertwee,et al.  Enhancement by chlordiazepoxide of catalepsy induced in rats by intravenous or intrapallidal injections of enantiomeric cannabinoids , 1991, Neuropharmacology.

[75]  R. Steger,et al.  Δ9-Tetrahydrocannabinol antagonism of the anterior pituitary response to estradiol in immature female rats , 1991, Steroids.

[76]  M. Herkenham,et al.  Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[77]  T. Bonner,et al.  Structure of a cannabinoid receptor and functional expression of the cloned cDNA , 1990, Nature.

[78]  G. E. Alexander,et al.  Functional architecture of basal ganglia circuits: neural substrates of parallel processing , 1990, Trends in Neurosciences.

[79]  M. Herkenham,et al.  Cannabinoid receptor localization in brain. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[80]  A. Bartke,et al.  Effects of delta-9-tetrahydrocannabinol, cannabinol and cannabidiol, alone and in combinations, on luteinizing hormone and prolactin release and on hypothalamic neurotransmitters in the male rat. , 1990, Neuroendocrinology.

[81]  Effects of delta-9-tetrahydrocannabinol on sensory evoked hippocampal activity in the rat: principal components analysis and sequential dependency. , 1989, The Journal of pharmacology and experimental therapeutics.

[82]  A. Howlett,et al.  Determination and characterization of a cannabinoid receptor in rat brain. , 1988, Molecular pharmacology.

[83]  G. Di Chiara,et al.  Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[84]  G. Snyder,et al.  Hypothalamic action of delta-9-tetrahydrocannabinol to inhibit the release of prolactin and growth hormone in the rat. , 1988, Neuroendocrinology.

[85]  R. Pertwee The central neuropharmacology of psychotropic cannabinoids. , 1988, Pharmacology & therapeutics.

[86]  T. Teyler,et al.  The modulation of long-term potentiation by delta-9-tetrahydrocannabinol in the rat hippocampus, in vitro , 1987, Brain Research Bulletin.

[87]  R. Hampson,et al.  Effects of delta 9-tetrahydrocannabinol on sensory-evoked discharges of granule cells in the dentate gyrus of behaving rats. , 1986, The Journal of pharmacology and experimental therapeutics.

[88]  R. Hampson,et al.  delta 9-Tetrahydrocannabinol differentially affects sensory-evoked potentials in the rat dentate gyrus. , 1986, The Journal of pharmacology and experimental therapeutics.

[89]  J. Brady,et al.  Behavioral analysis of marijuana effects on food intake in humans , 1986, Pharmacology Biochemistry and Behavior.

[90]  L E Hollister,et al.  Health aspects of cannabis. , 1986, Pharmacological reviews.

[91]  A. Howlett,et al.  Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. , 1986, Molecular pharmacology.

[92]  L. Tyrey Reversal of the delta-9-tetrahydrocannabinol inhibitory effect on prolactin secretion by rostral deafferentation of the medial basal hypothalamus. , 1986, Neuroendocrinology.

[93]  L. Murphy,et al.  Induction of luteinizing hormone release by electrochemical stimulation of the medial preoptic area in delta 9-tetrahydrocannabinol-blocked proestrous rats. , 1986, Neuroendocrinology.

[94]  R. Harris,et al.  Effects of the cannabinoids on physical properties of brain membranes and phospholipid vesicles: fluorescence studies. , 1985, The Journal of pharmacology and experimental therapeutics.

[95]  A. Bloom,et al.  The effects of δ9-tetrahydrocannabinol on serum thyrotropin levels in the rat , 1984, Pharmacology Biochemistry and Behavior.

[96]  R. Steger,et al.  Interactions of delta 9-tetrahydrocannabinol (THC) with hypothalamic neurotransmitters controlling luteinizing hormone and prolactin release. , 1983, Neuroendocrinology.

[97]  A. Fitton,et al.  CHANGES IN BODY TEMPERATURE AND OXYGEN CONSUMPTION RATE OF CONSCIOUS MICE PRODUCED BY INTRAHYPOTHALAMIC AND INTRACEREBROVENTRICULAR INJECTIONS OF Δ9‐TETRAHYDROCANNABINOL , 1982, British journal of pharmacology.

[98]  C. Hughes,et al.  Delta 9-tetrahydrocannabinol suppression of prolactin secretion in the rat: lack of direct pituitary effect. , 1981, Endocrinology.

[99]  R. Steger,et al.  The effects of delta 9-tetrahydrocannabinol on the positive and negative feedback control of luteinizing hormone release. , 1980, Life sciences.

[100]  M. Hosko,et al.  Hypothermic effects of intraventricular and intravenous administration of cannabinoids in intact and brainstem transected cats , 1980, Neuropharmacology.

[101]  J. Dean,et al.  Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. , 1979, The New England journal of medicine.

[102]  S. London,et al.  Suppression of Cancer Chemotherapy-Induced Vomiting in the Cat by Nabilone, a Synthetic Cannabinoid 1 , 1979, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[103]  A. Bartke,et al.  Direct and pituitary-mediated effects of Δ 9-THC and cannabinol on the testis , 1978, Pharmacology Biochemistry and Behavior.

[104]  L. Tyrey delta-9-Tetrahydrocannabinol suppression of episodic luteinizing hormone secretion in the ovariectomized rat. , 1978, Endocrinology.

[105]  I. Nir,et al.  Acute effect of delta1-tetrahydrocannabinol on the hypothalamo-pituitary-ovarian axis in the rat. , 1977, Neuroendocrinology.

[106]  S. Sallan,et al.  Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. , 1975, The New England journal of medicine.

[107]  A. Sheth,et al.  Effect of Acute Δ9-Tetrahydrocannabinol Treatment on Serum Luteinizing Hormone and Prolactin Levels in Adult Female Rats , 1975 .

[108]  V. Houser The effects of Δ9-tetrahydrocannabinol upon fear-motivated behavior in squirrel monkeys , 1975 .

[109]  Joseph F. Garcia,et al.  Effects of Δ9 - THC on growth hormone and ACTH secretion in rats , 1974 .

[110]  I. Nir,et al.  Suppression of the Cyclic Surge of Luteinizing Hormone Secretion and of Ovulation in the Rat by Δ1-Tetrahydrocannabinol , 1973, Nature.

[111]  H. Barry,et al.  Corticosterone elevation mediated centrally by Δ1-tetrahydrocannabinol in rats , 1971 .

[112]  L. Harris,et al.  The effect of 1-trans-delta 9-tetrahydrocannabinol on the hypothalamo-hypophyseal-adrenal axis of rats. , 1970, European journal of pharmacology.

[113]  J. Jaffe,et al.  1-δ9-Tetrahydrocannabinol: Neurochemical and Behavioral Effects in the Mouse , 1969, Science.

[114]  R. Mechoulam,et al.  Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish , 1964 .